Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth

Mandaviya chairs 7th meeting of Central Institute Body of AIIMS and Chintan Shivir at NIHFW, Delhi

Chintan Shivir has provided a platform to hold discussions with higher officials and experts, which will help in evolving better practices of premier health institutions like AIIMS

Eugia Pharma receives USFDA approval for Plerixafor Injection

The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023

TransCure bioServices partners with Preclina to expands reach into APAC

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders

Akums gets approval for triple combination diabetes treatment

Apollo performs 23000+ multi-organ transplantation

Apollo Transplant program is the first program in India to cross the landmark of 18500 kidney transplants, 4300 liver transplants and 500 pediatric liver transplants

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business

M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData

CMOs showed an increasing reluctance to take on debt in 2022